Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
For patients doing well on targeted therapies (alectinib, osimertinib) for metastatic NSCLC, what data / guidelines do you use to decide about holding treatment before/after surgical procedures?
Related Questions
How do you typically approach adjuvant therapy for a Masaoka stage IVa thymoma post-R0 resection?
Would you consider adjuvant osimertinib for NSCLC with an EGFR E746_S752delinsV exon 19 mutation?
Is there any data supporting the use of osimertinib in patients with L858R-mutated lung cancer who had a durable response to prior EGFR TKI therapy, and who progressed 1-2 years after discontinuation of other EGFR inhibitors?
When, if at all, do you utilize neoadjuvant chemotherapy alone for resectable, Stage II NSCLC with mutations such as EGFR or ALK?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
How are you incorporating Tumor Treating Fields for locally progressive/metastatic NSCLC, if at all?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
